Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
No abstract available.
. The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines. .
Item in Clipboard